Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Inflammatory Bowel Disease
•
Gastroenterology
When do you consider de-escalation from combination therapy with anti-TNFs and thiopurines to monotherapy with anti-TNFs in patients with IBD?
Answer from: at Academic Institution
I withdraw the thiopurine if after 1 year the patient has achieved the goals of care.
Sign In
or
Register
to read more
25838
Related Questions
In patients who have failed 5-ASA and have moderate to severe UC, do you utilize 5-ASA as an adjunct, especially rectal therapy?
How do you approach the treatment of Crohn's colitis in the setting of immunosuppression for liver transplant?
After confirming the patient is not on NSAIDs, how do you approach acute ileitis on biopsies in a patient without symptoms or with only mild loose stools?
If an IBD patient has only partial clinical response to a new biologic and or small molecule, do you extend the loading phase before transitioning to the maintenance dose/interval? How do you navigate insurance coverage?
How would you manage an asymptomatic patient after VCE showing small bowel Crohn's who passes the patency capsule but has retained the video capsule in the distal ileum with minimal surrounding inflammation?
What techniques do you find most effective for visualization of rectal disease with intestinal ultrasound?
In patients with longstanding UC or Crohn's colitis, would you extend the interval of surveillance colonoscopy to longer than 3 years if they have had little inflammatory disease over the years and no other factors to increase their risk (ie, history of polyps, history of dysplasia, or family history)?
What are your vaccine recommendations while patients are on biologics?
What is your approach to managing ILD associated with inflammatory bowel disease?
In an infant whose mother resumes TNF inhibitor therapy (e.g., adalimumab, infliximab, certolizumab) after delivery and is breastfeeding, do you recommend delaying live vaccinations?